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Background: Chronic obstructive pulmonary disease (COPD) is characterized by irreversible, progressive obstruction
of lung airflow. Dyspnea (shortness of breath [SOB]) is the COPD symptom which most negatively impacts patients’
daily activities. To assess how SOB affects daily activities, 37 items were drafted through focus group discussions
and cognitive interviews with COPD patients to develop a patient-reported outcome instrument: the Shortness of
Breath with Daily Activities questionnaire (SOBDA). Psychometric analysis was conducted to reduce the number of
items and evaluate the measurement properties of the final SOBDA.
Methods: Prospective, observational study of 334 COPD patients, recruited from 24 pulmonology and internal
medicine clinics in the United States. The 37-item SOBDA was administered to patients each evening for 28 days
using an electronic diary. Patients answered every item and rated their level of SOB experienced that day during
specific activities. Item selection was conducted by examining item characteristics, dimensionality, and Rasch model
analysis results. The decision to delete an item was based on psychometric evidence, content validity, and expert
clinical input. The final SOBDA instrument was evaluated for internal consistency, reproducibility, convergent validity,
known-groups validity, and responsiveness.
Results: Twenty-four items from the 37-item pool were removed following the item selection process: nine items
were removed due to high item-to-item correlations; five due to floor effects; three due to infrequent activity; one
due to gender bias; two due to low factor loadings; three due to unordered response options; and one due to
expert’s discretion. Internal consistency and reproducibility of the final SOBDA were demonstrated by Cronbach
Alpha = 0.87, and intra-class correlation coefficient = 0.91. Convergent validity was demonstrated by high correlation
with the CRQ-SAS (0.60) and SGRQ-C (0.61). Known groups validity was demonstrated by significant difference
between ratings of the mMRC and clinical global rating of severity. Evaluation of the ability to detect change was
not performed owing to too few responders at the end of the study.
Conclusions: Through the empirical item reduction process, 13 items were selected from the 37-item pool generated
during qualitative development. The final 13-item SOBDA is a reliable and valid instrument for use in clinical trials.
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Dyspnea, or shortness of breath (SOB), is a common and sig-
nificant symptom of chronic obstructive pulmonary disease
(COPD) and the most frequently cited reason for patients to
seek medical attention [1]. The quality of life of patients with
COPD is dramatically affected by the decline in functional
status and physical activity associated with SOB [1-4].
Measurements of lung function such as forced expira-
tory volume in 1 second (FEV1) are the primary parame-
ters used to monitor airflow limitation in COPD. However,
lung function correlates poorly with the symptoms of
COPD, including SOB, and may not reflect the symptom-
atic changes that are important to patients [1,5]. Monitor-
ing the effect of treatment on SOB is important and can
only be conducted from the patient’s perspective. Currently
available instruments for assessing patient-reported symp-
toms of COPD, such as the Chronic Respiratory Question-
naire Self-Administered Standardised (CRQ-SAS) [6-8]
and St. George’s Respiratory Questionnaire for COPD pa-
tients (SGRQ-C) [9-11], do not specifically focus on the
concept of SOB associated with daily activity, being much
broader in scope. In addition, there are no available instru-
ments that support a SOB-specific claim for a medicinal
product in the United States. As such, there is a need for a
patient-reported outcome (PRO) measure that specifically
addresses SOB associated with daily activities in COPD,
and monitors change over time in response to treatment
that can be used in clinical trials.
The Shortness of Breath with Daily Activities (SOBDA)
questionnaire was specifically designed as an electronic
patient-reported instrument to evaluate the impact of
treatment on SOB in patients with COPD; its qualitative
development has been previously described in detail [12].
Briefly, the development involved three distinct steps –
focus groups, item development, and cognitive interviews –
before items for the questionnaire were drafted. Focus
groups of patients with a physician diagnosis of COPD
were asked to describe their experiences of SOB during
their daily activities. Based on this research and current
literature reviews, a pool of items was drafted and subse-
quently discussed with instrument development experts
and COPD clinical experts. Cognitive debriefing inter-
views that assessed the draft item pool were then con-
ducted, and patient feedback was used to revise and
update the items on the questionnaire.
The current study examined the measurement properties
in order to reduce the number of items in the 37-item draft
SOBDA questionnaire. The reliability, validity and respon-
siveness of the refined instrument were also assessed.
Methods
Study design
During the first stage of development [12], focus groups
were held with COPD patients to explore concepts andthemes related to SOB with daily activities. A total of
seven groups (40 patients) were held to achieve concept
saturation (no new descriptors or activities identified).
After the initial questions (items) were drafted, cognitive
debriefing interviews with 37 patients assessed this draft
pool and provided feedback that was used to update and
revise the items. Items included in the pool reflected
both different levels of strenuousness and different body
positions, as both have been demonstrated to be import-
ant in the subjective experience of dyspnea [3]. Clinicians,
translational and lexibility experts were also consulted
during the development process, and their input was in-
corporated into the questionnaire. The questionnaire was
developed in line with the United States Food and Drug
Administration (FDA) PRO guidance document stating
that any PRO instrument must demonstrate evidence of
reliability, validity, and ability to detect change [13]. The
FDA (Division of Pulmonary, Allergy, and Rheumatology
Products with consultation from Study Endpoints and
Label Development Team, Office of New Drugs, Center
for Drug Evaluation and Research) was also consulted dur-
ing the development process.
The current stage of development, as reported here,
was a prospective, observational study of patients with
COPD (GlaxoSmithKline protocol 107364; Evidera A-
4398) from 24 pulmonology and internal medicine clinics
across the United States. Data were collected from January
to September 2009. Patients were recruited with all levels
of lung function to ensure that the final SOBDA was ap-
propriate for use in all disease severities.
Two study visits were scheduled on Days 1 and 28. The
study protocol and recruitment procedures met all Institu-
tional Review Board and Health Insurance Portability and
Accountability Act requirements, as well as applicable
state and federal laws and regulations. Each participant
provided written informed consent. The study was ap-
proved and monitored by Essex Institutional Review
Board (Lebanon, New Jersey, USA).
Study sample
Participants with all stages of COPD severity, as defined by
the Global Initiative for Chronic Obstructive Pulmonary
Disease (GOLD) guidelines [1], were recruited; see Table 1
for a full list of entry criteria. Maintenance medications
were limited to stable prescriptions of inhaled long-acting
beta-agonists, long-acting muscarinic antagonists, inhaled
corticosteroids, long-acting beta-agonist/inhaled cortico-
steroid combination products, and/or Combivent®. Patients
who were not previously prescribed maintenance medica-
tions were also included in the study population.
Assessments and measures
Assessments completed by the clinician and patients
are shown in Table 2. At Visit 1, patients completed a
Table 1 Inclusion and exclusion criteria
Key criteria
Inclusion Exclusion
Current clinical diagnosis of
COPD based on the GOLD
2008 guideline criteria [20]
Ages 40–80 years
Current or former smoker
with smoking history of ≥ 10
pack-years
Evidence of SOB confirmed
by clinician mMRC dyspnea
rating of ≥ 2 for GOLD
spirometric classifications
II–IV patients
Experienced an exacerbation in the
60 days preceding enrolment
Concurrent diagnosis of asthma
Known respiratory disorders other
than COPDa
Organic heart disease with resultant
left ventricular failure and New York
Heart Association class 2–4
Known neuromuscular disease
aα-1 antitrypsin deficiency as the underlying cause of COPD, active
tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary
hypertension and interstitial lung disease.
COPD Chronic obstructive pulmonary disease.
mMRC Modified Medical Research Council.
Table 2 Study assessments








































bThe 6-MWT was completed by a subset of patients.
6-MWT 6-Minute Walk Test.
CGI-C Clinician Global Impression of Change.
CGI-S Clinician Global Assessment of Dyspnea Severity.
CRQ-SAS Chronic Respiratory Questionnaire Self-Administered Standardised.
MBD Modified Borg Dyspnea Scale.
mMRC Modified Medical Research Council Grading System.
PGAC Participant Global Assessment of Change.
RPE Rating of Perceived Exertion scale.
SGRQ-C St. George’s Respiratory Disease Questionnaire for COPD Patients.
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ministration) [6-8]; the SGRQ-C [9-11]; and the Modified
Medical Research Council Dyspnea scale (mMRC; patient
completed) [14]. Investigators completed a clinical ques-
tionnaire, mMRC scale, and Clinician Global Assessment
of Dyspnea Severity (CGI-S). Study centers also conducted
spirometry on all patients. At a predefined subset of clin-
ical sites patients also completed a 6-Minute Walk Test
(6-MWT) [15] and Borg rating scales (the Modified Borg
Dyspnea Scale Participants [MBD] and the Borg Rating of
Perceived Exertion Scale [RPE]) [16,17].
Patients received training on Day 1 for the electronic
Diary (eDiary), used to administer the 37-item draft
SOBDA questionnaire each evening for 28 days. Items
asked the patient to rate their level of SOB experienced
during an activity. All eDiaries were returned at Visit 2
(Day 29–32). Additional information gathered each day
via the eDiary included a global assessment of SOB, in-
stances of healthcare provider contact, and rescue medi-
cation use. A personalized built-in alarm alerted patients
to complete the eDiary 1 hour prior to their normal bed
time. Patients transmitted data from the eDiary on a
daily basis, and adherence was monitored via a dedicated
web portal.
All patients completed the CRQ-SAS (follow-up ad-
ministration), SGRQ-C, and mMRC (patient-completedform) and spirometry assessment at Visit 2. A second 6-
MWT was also completed in the subset of sites. An exit
evaluation of perceived patient burden associated with
completing the eDiary on a daily basis was also com-
pleted. Investigators completed a follow-up clinical ques-
tionnaire, mMRC scale and Clinical Global Impression of
Change (CGI-C). Unscheduled healthcare utilization and
any medication changes between Visits 1 and 2 were also
recorded for potential use in exploratory analyses. Patients
with poorly controlled SOB often require additional
healthcare attention and may change medications more
frequently than patients with SOB that is well tolerated.
Statistical analysis
All patients with ≥ 1 day of eDiary data were included in
the analysis for item reduction, scoring and scaling as-
sessments, and for the psychometric analysis. The eDiary
did not allow individual items to be skipped, but it was
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specified, Day 1 data were used for the item psychomet-
ric analyses. Where Day 1 data were missing, the first
diary entry completed was used. The frequency and pos-
sible reasons behind missing diary entries were exa-
mined by attempting to link days without a diary entry
with data collected on the scheduled and unscheduled
healthcare utilization and participant contact case report
forms, as well as the participant’s report of healthcare
provider contact on the preceding days.
Item reduction
Item reduction was conducted by examining item char-
acteristics, dimensionality, and the results of Rasch
model analysis (see below for additional details, Rasch
model analysis). The final decision to delete an item was
based on the psychometric evidence, the content validity
of the items, and expert clinical input. Day 1 diary data
were used to assess the distributional characteristics of
the individual SOBDA items; initial values were assigned
to each category from 0 (‘I did not do the activity today’)
to 5 (‘So severe that I did not do the activity today’). The
mean, percentages of minimum and maximum responses
(to determine floor and ceiling effects), item-total correl-
ation, frequencies of item responses, and inter-item corre-
lations were examined. An item was flagged for deletion if
it had a floor (minimum response given by > 30% patients)
or ceiling effect (maximum response given by > 50% pa-
tients). Additionally, items were flagged for deletion when
the inter-item correlation was > 0.70, indicating duplica-
tion within the item pool; or the item-total correlation
was < 0.20, indicating the question was measuring a con-
cept different from the other questions in the item pool.
Gender and age were examined to ensure that these fac-
tors did not contribute to how patients responded to the
SOBDA items and prevent inherent biases in the final
questionnaire; the cut-offs for these bias factors, gender
and age, were set at 6% shared variance. In addition, a cut-
off was set at 4% shared variance with the external criter-
ion (clinician-rated dyspnea severity).
Confirmatory factor analysis (CFA): assessment of
dimensionality
CFA was conducted to determine whether the remaining
items formed a uni-dimensional construct suitable for
Rasch analysis. That is, all items which comprised the
instrument measured the same construct (SOB with
daily activities), and differed only by the levels of severity
each of the items measured. Model fit was assessed
using the comparative fit index (CFI), root mean square
error of approximation (RMSEA) and standardized root
mean square residual (SRMR). Good fit was defined as:
> 0.90 CFI, and both RMSEA and SRMR < 0.05. Mplus
software was used for factor analysis [18].Rasch model analysis
With the Rasch model, the probability of the patient
responding to an item is modeled by a logistic function,
with the assumption that a patient is more likely to re-
spond to an item that reflects his/her condition [19].
Data were fit to a Rasch model with RUMM 2020 [20],
and chi-square fit statistics were used to assess overall
model and individual item fit. Item response thresholds
and category probability curves were examined, and dis-
ordered response options were corrected by collapsing
categories (e.g. ‘not at all’ and slightly’).
Evaluation of measurement: reliability and validity
Internal reliability and validity were assessed with Cronbach’s
Alpha and intra-class correlation (ICC) coefficients, respect-
ively. The relationship between SOBDA scores and other
measures (convergent validity) was assessed with Pearson’s
correlation coefficient (6-MWT, SGRQ-C, CRQ-SAS, FEV1%
predicted) or Spearman rank order correlation (mMRC
score at Visit 1, MBD, RPE). The ability of the SOBDA to
discriminate between clinically diverse groups (known
groups validity) was assessed with analyses of variance in
patients grouped by mMRC rating (clinician and patient),
CGI-S rating, and GOLD stage. Construct validity was
demonstrated through Pearson’s correlations with hypoth-
esized variables (mMRC scores, CRQ-SAS domain scores,
SGRQ-C).
Results
Patient flow is shown in Figure 1, and patient demo-
graphic characteristics are summarized in Table 3. Of
the 406 patients enrolled in the study, 67 patients were
excluded from the analysis because of screen failures, in-
cluding eight patients who were excluded due to Visit 1
protocol deviation. Five patients had no eDiary data. The
final analysis population consisted of 334 patients. The
mean age was 62.3 years and the majority of patients
were White (76.9%). Approximately half of the popula-
tion was male (52.1%) and current smokers (49.4%).
The mean time since COPD diagnosis was 7.4 years
(Table 4) and, although patients with all levels of severity
were included in the study, the majority of patients were
classified by spirometry as GOLD Stage II (40.1%) or
Stage III (34.1%). A similar distribution was also ob-
served based on symptom severity (47.0% moderate;
30.2% severe) and symptoms as rated by clinicians com-
pleting a global impression of severity of SOB scale
(48.5% moderate; 28.7% severe).
Item analysis
Of the 37 items, a total of 19 less relevant items were
deleted from the original pool through item analysis; 10
of these were deleted due to high item-to-item correla-
tions (duplication). The other nine items were deleted
Figure 1 Patient flow.
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activity (three items), and gender bias (one item). The
rationale for deletion or acceptance is shown in Figure 2.
Additional items were later deleted from the pool based
on CFA and Rasch model analysis.
CFA: assessment of dimensionality
When CFA was conducted on the remaining 18 items in
the reduced pool, the fit statistics (CFI = 0.837, RMSEA =
0.149, SRMR= 0.079) did not meet pre-defined criteria.
Two items were identified for exclusion (‘make bed’ and
‘eating’) and were deleted based on low factor loading,
leaving 16 items for further CFA. CFA on the remaining
items did not substantially improve the fit statistics (CFI =
0.850, RMSEA = 0.150, SRMR = 0.080) but a general fac-
tor was strongly suggested by the high factor loadings.Table 3 Patient demographics
Patient characteristic Population for analysis
(N = 334)
Age, mean (SD) 62.3 (9.66)
Male gender, n (%) 174 (52.1)
Race/ethnicity, n (%)a
American Indian or Native 8 (2.4)
Asian 39 (11.7)
Black or African American 15 (4.5)
Hispanic or Latino 18 (5.4)
Native Hawaiian or Other Pacific Islander 2 (0.6)
White 257 (76.9)
Other 3 (0.9)
Tobacco history, n (%)
Current smokers 165 (49.4)
Former smokersb 169 (50.6)
Number of years since stopped
smoking, mean (SD)
10.6 (9.15)
aPatients marked all that applied.
bFormer smoker defined as not smoked within 6 months of Visit 1.
SD Standard deviation.Recognizing that further removal of items would not
improve the CFA fit statistics, Rasch model analysis was
used to identify additional items for further exclusion.
Rasch model analysis
Four items were removed from the 16-item pool based
on Rasch model analysis (three items whose response
options were not ordered and could not be collapsed;
one item based on experts’ discretion). The one item
(‘walked up 8 stairs’) deleted during the earlier item ana-
lysis due to its high correlation with two other items
(‘walked up 3 stairs’ and ’walked up 8 stairs fast’) was
re-instated due to its high relevance for measuring breath-
lessness in less severe patients and following recommen-
dation by the expert clinical panel. A total of 13 items
remained as a result of the item reduction process and
formed a valid uni-dimensional scale, that is, all 13 items
measured the same underlying construct of “SOB with
daily activities”. The overall Rasch model fit had a chi-
square of 88.48, degrees of freedom = 52, p = 0.001, andTable 4 Clinical characteristics
Characteristics Visit 1
(N = 334)
COPD diagnosis (years), mean (SD) 7.4 (6.6)
Chronic bronchitis, n (%) 90 (26.9)
FEV1% predicted (%), mean (SD) 51 (18.9)
COPD GOLD spirometric classification, n (%)a,b
At risk 18 (5.4)
GOLD I (FEV1≥ 80% predicted) 19 (5.7)
GOLD II (50%≤ FEV1 < 80% predicted) 134 (40.1)
GOLD III (30%≤ FEV1 < 50% predicted) 114 (34.1)
GOLD IV (FEV1 < 30%) 48 (14.4)
aGOLD spirometric classification determined by Visit 1 post-bronchodilator
spirometry assessment. bMissing (n = 1).
COPD Chronic obstructive pulmonary disease.
FEV1 Forced expiratory volume in 1 second.
SD Standard deviation.
Figure 2 Rationale for item rejection or acceptance in the 37-item pool for the SOBDA questionnaire.
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ability. Chi-square statistics for individual item test-of-fit
were not significant (p > 0.05) in 12 items; one item with
p = 0.005.
Scoring
When item reduction was complete, a finalized scoring
system was created for the SOBDA questionnaire. The
intent was to develop a scoring scheme that was consist-
ent with the underlying framework and the empirical
evidence of construct (i.e. items grouping around one
main concept) derived through the analyses outlined
above. The ‘did not do the activity today’ response was
considered a missing score; other response categories
were assigned ordinal scores based on the associated
level of severity. Each daily SOBDA score was computed
from the mean of the scores of the 13 items when there
were at least seven scores not missing. The daily SOBDA
score ranges from 1–4 with greater scores indicating
more severe breathlessness with daily activities.
Daily scores frequently showed a wide variation in a
patient’s activities from day to day, and therefore may
not have accurately represented a patient’s overall ex-
perience of SOB related to activity. Mean scores for 2 or
more days were therefore examined to determine which
averaged values provided the most information. Weekly
SOBDA scores were chosen as they accounted for the
day-to-day variability and provided the best summary of
overall experience of SOB . The final scoring algorithm
therefore assigned each patient a weekly mean SOBDA
score ranging from 1–4 with greater scores indicatingmore severe SOB with daily activities. The weekly score
was calculated from the mean of the daily scores if data
were available for at least 4 out of 7 days; the mean (SD)
weekly score was 1.8 ± 0.6 (Week 1) and 1.8 ± 0.7
(Weeks 2–4), and the median weekly SOBDA score was
1.6 (range 1.0–4.0) across the 4 weeks of the study.Reliability and validity
SOBDA scores showed strong internal consistency and
test-retest reliability. At Day 1, the internal consistency
among the items (Cronbach’s Alpha) was 0.87; when in-
dividual constituent items were deleted values ranged
from 0.85 to 0.87, indicating that no further item reduc-
tion was required. Assessment of weekly score test-retest
reliability used the Participant Global Assessment of
Change (PGAC) response of ‘no change’ to define stable
patients. In these patients, Pearson’s correlation values
were high and ICC coefficients were 0.91 for Week 1 to
Week 2 and 0.87 for Week 1 to Week 4. In addition, dif-
ferences in scores for Week 2 vs. Week 1 and Week 4
vs. Week 1 were small.Convergent validity
SOBDA weekly average scores showed appropriate con-
vergent validity based on high correlation with other mea-
sures (Table 5). A strong relationship was observed
between SOBDA, the dyspnea domain of the CRQ-SAS,
and the activity domain of the SGRQ-C. The association
between mean SOBDA scores during Week 1 and FEV1%
predicted values from the Visit 1 spirometry was assessed.
Table 5 Correlations between SOBDA week 1 and FEV1%
predicted, mMRC, 6-MWT, and COPD health status
SOBDA n Total score
FEV1% predicted
a,b (n = 290) –0.23*
mMRCa
Patientd (n = 292) 0.46*
Cliniciand (n = 292) 0.44*
6-MWTa,c
Pre-MBDd (n = 74) 0.62*
Post-MBDd (n = 74) 0.58*
Borg RPEd (n = 74) 0.63*
Distanceb (n = 74) –0.46*
COPD health statusa
SGRQ-C totald (n = 287) 0.73*
SGRQ-C symptom (n = 290) 0.53*
SGRQ-C activity (n = 290) 0.73*
SGRQ-C impact (n = 288) 0.62*
CRQ-SAS dyspnead (n = 291) –0.76*
aMeasured as Visit 1.
bPearson's correlation.
c6-MWTs were done at a subset of sites.
dSpearman's rank-order correlation.
*p < 0.0001.
6-MWT 6-Minute Walk Test.
COPD Chronic obstructive pulmonary disease.
CRQ-SAS Chronic Respiratory Questionnaire Self-Administered Standardised.
FEV1 Forced expiratory volume in 1 second.
MBD Modified Borg Dyspnea Scale.
mMRC Modified Medical Research Council.
RPE Rating of Perceived Exertion Scale.
SGRQ-C St. George’s Respiratory Disease Questionnaire for COPD Patients.
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(FEV1% predicted) was relatively weak (r = –0.16) [1,5].Known-groups validity
SOBDA scores increased as patient and clinician mMRC
ratings of severity increased, with more accurate dis-
crimination observed for patient vs. clinician ratings.
Analysis of Covariance (ANCOVA) showed that all pair-
wise comparisons of SOBDA scores between CGI-S rat-
ings were significant (p < 0.05) with the exception of
mild vs. moderate, and severe vs. very severe. Discrimin-
ation by GOLD stage was not observed, which was ex-
pected due to the low correlations between FEV1%
predicted, SOBDA, and other PRO measures at Visit 1.Responsiveness
In this study there was no significant difference between
responders (those who reported global improvement as
‘better’ or ‘much better’) and non-responders (those who
reported no change, ‘worse’ or ‘much worse’); this is most
likely due to the low number of patients reporting change
(n = 4). Identification of a meaningful importance differencethreshold was also explored, but the small sample size of
responders prevented robust interpretation.
Discussion
The development of item content and response options
for the SOBDA questionnaire has been previously dis-
cussed [12]. This study was designed to appropriately re-
duce the number of items in the 37-item draft SOBDA
questionnaire, and to examine the measurement proper-
ties: assessing the reliability, validity and responsiveness
of the resultant instrument. The results demonstrate that
the 13-item SOBDA is a reliable and valid tool for daily
assessment of SOB during daily activities in patients
with COPD for use in clinical research.
The internal consistency and reliability of the SOBDA
total scores were demonstrated by the Cronbach Alpha of
0.87 and person separation index of 0.86 [21]. In addition,
the SOBDA showed good reproducibility (ICC = 0.91) in
patients reporting no change in their SOB (measured by
the PGAC). Rasch and factor analyses further supported
content validity, established uni-dimensionality, and con-
firmed that there were no gaps in measurement. Appro-
priate construct validity was also confirmed through
Spearman rank order correlations with pre-specified
variables including mMRC, MBD and RPE scores and
Pearson’s correlations with 6-MWT distance, FEV1%
predicted, CRQ-SAS domain scores and the SGRQ-C.
Furthermore, a strong relationship was demonstrated
between the SOBDA and the related dyspnea domain of
the CRQ-SAS and activity domain of the SGRQ-C.
These results provide evidence supporting the construct
validity of the instrument, which is designed to measure
SOB associated with activity. Although the relationship
between SOBDA scores and mMRC was lower than ex-
pected, this association may have been affected by study
inclusion criteria, which required patients to be symp-
tomatic (mMRC ≥ 2) at screening. Although mMRC is
often used for patient stratification within studies, it has
previously been shown to be unresponsive to change
and not sensitive enough to demonstrate a treatment ef-
fect in clinical trials [22,23]; this can be viewed as a limi-
tation of this study. It should be noted, however, that no
restriction on mMRC was used in recruiting patients
with COPD for the qualitative stage of questionnaire de-
velopment where the 37-items used in this study were
developed [12]. The criteria used to recruit the patient
population for this study are similar to those used in re-
cruitment of clinical trials including the program where
the SOBDA was initially used. These criteria are also
consistent with FDA requirements for a clinical trial for
symptom relief [13].
Both the FDA and the European Medicines Agency
have recently emphasized the importance of reflected
patient experience in clinical trials [13,24], as objective
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provements; SOBDA can be utilized to provide these
data. This further demonstrates the importance of deve-
loping a daily PRO instrument that specifically addresses
SOB associated with daily activities in patients with
COPD, which can monitor change over the course of
treatment.
The low association between FEV1% predicted values
and mean SOBDA scores was expected and is similar to
results of other studies showing low levels of association
between FEV1 and COPD symptoms, including SOB
[1,5,25]. Results from the predefined subset of clinical
sites which conducted exercise testing (patients com-
pleted the 6-MWT, MBD and RPE assessments) did not
affect construct validity. These exercise assessments
were not the primary endpoints of the study and did not
influence the overall results.
Although responsiveness of the SOBDA was examined,
almost all patients recruited to the study reported stable
disease throughout the study period. The small sample
of patients defined as responders (n = 4) prevented
meaningful interpretation, which is another limitation of
this study. However, an interventional study to define a
responder threshold and confirm the responsiveness of
the SOBDA was conducted and is reported separately
[26]. That study expanded the current knowledge of the
differences in scores among people with varying levels
of severity of dyspnea and provided information on
responsiveness.
It is important to note that the item pool evaluation
used to achieve the 13-item questionnaire, and develop-
ment of the questionnaire scoring were both conducted
empirically to optimize the balance between patient bur-
den in completing a daily questionnaire and measurement
validity. To measure changes over time in symptoms such
as SOB, which may vary on a daily basis, data collection
using a diary is preferred as patients are more likely to re-
call their level of SOB while performing each activity ac-
curately. This daily measurement of symptoms is also in
line with guidance from the FDA for the development of a
new PRO instrument [13]. Data collection methods where
the daily entries are date and time stamped, such as the
eDiary used in this study are also preferred.
The final SOBDA includes a number of different activ-
ities reflecting different levels of exertion and body posi-
tions which have been shown to impact a patient’s
experience of SOB [3,12]. It was determined that the opti-
mal method for scoring of the SOBDA was to use a
weekly mean score (requiring data on at least 4 of the
7 days), based on the possibility that a patient may not
conduct all daily activities each day. A weekly score is
likely to maximize the available information provided by
SOBDA without loss of responsiveness. In finalizing the
scoring algorithm, it was important to ensure that patientswere able to distinguish between the two options of ‘I did
not do the activity today’ and ‘So severe that I did not do
the activity today’. A response evaluation was therefore
conducted, which included a re-examination of the quali-
tative research [12] and data from the current study, be-
fore finalising SOBDA scoring. Evaluation across the final
13 items over a 7-day period identified between 0–15 indi-
viduals (n = 334 responses) who endorsed both ‘I did not
do the activity today’ and ‘So severe I did not do the activ-
ity today’ for a given item on different days suggesting that
patients can distinguish between the two response op-
tions. However, implementation and scoring of this tool in
a clinical trial setting would require further evaluation.
In respiratory clinical trials, patient-reported data his-
torically have been collected through structured inter-
views and self-reported questionnaires, which may
provide rich but not easily comparable data, and visual
analogue or other numeric scales which may not ad-
equately distinguish change with treatment [27,28].
While the patient-reported aspects of COPD have been
assessed using currently available questionnaires, many
instruments focus solely on symptom severity [6-11],
and do not assess SOB with activity, which may be more
meaningful to the patient. These tools are therefore not
appropriate for drug development purposes where SOB
with daily activity is the primary focus. For those instru-
ments that include an assessment of SOB with activity,
no consideration is given to posture, a critical compo-
nent identified in the SOB endpoint rationale [3]. In
addition, not all available assessments have been empir-
ically validated to the standard required by the FDA
guidance [13]. While including items related to activity,
the CRQ-SAS [6-8] and the SGRQ [9-11] are instru-
ments that measure multiple dimensions and are much
broader in scope than SOB with activity, the target for
the current SOBDA instrument.
Conclusions
The SOBDA questionnaire was developed to address the
need for a robust PRO instrument for use in clinical re-
search to capture SOB associated with daily activities for
patients with COPD. Through the use of quantitative
evaluation and empirically-based item reduction, this
prospective observational study successfully reduced the
pool of 37 items generated from the qualitative phase of
the questionnaire development to the final 13-item daily
questionnaire. The validity and uni-dimensional nature
of the final 13-item SOBDA questionnaire was also dem-
onstrated; it showed good overall Rasch model fit and
captured SOB along a single measurement scale, thus
supporting the use of a total score to represent SOB
with daily activities. The SOBDA questionnaire was
found to be a reliable and valid instrument for measu-
ring SOB with daily activity for COPD patients, and
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(responsiveness to change, response threshold, and min-
imal important difference) from a 6-week interventional
study are awaited with interest.Abbreviations
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